在预防衰老中使用西罗利斯的风险和益处
Journal of clinical pharmacology
|October 9, 2025
概括
西洛利斯对抗衰老有希望,但缺乏正式指导. 临床医生必须权衡非标注的衰老预防使用的风险和益处,并告知患者证据有限.
科学领域:
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 越来越多的公众对预防衰老和与年龄有关的疾病感兴趣.
- 塞罗利斯是FDA批准用于器官移植受体的药物,具有免疫调节和增长抑制的特性.
- 预防衰老的非标签使用西洛正在出现,但缺乏正式的指导方针.
研究的目的:
- 为了解决缺乏关于西洛斯剂量和用于预防衰老的管理的正式指导.
- 为临床医生提供建议,为抗衰老目的开处方西罗素的非标签.
主要方法:
- 审查关于西洛和衰老的当前文献.
- 对其药理性质和非标签用途的分析.
- 美国临床药理学学院的建议制定.
主要成果:
- 目前对于西洛斯在预防衰老方面没有正式的政策或立场文件.
- 建议临床医生仔细评估每个患者的风险益处概况.
- 患者必须充分了解非标签状态和有限的支持性证据.
结论:
- 处方西洛斯预防衰老需要仔细考虑,因为缺乏监管部门的批准和强有力的证据.
- 医疗保健提供者应与患者讨论现有的临床证据和正在进行的试验.
- 需要进一步的研究来确定西洛斯在预防衰老中的安全性,有效性和最佳剂量.
相关概念视频
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
234
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
234
Pharmacodynamics in Geriatric Patients: Effects of Age
187
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
187
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
196
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
196
Drug Dosing: Geriatric Patients
225
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
225
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
227
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
227


